Editorial: The role of gut microbiota in immune-related inflammatory diseases

This editorial, published in Frontiers in Cellular and Infection Microbiology, synthesizes findings from a curated Research Topic examining how the gut microbiota drives immune-related inflammatory diseases. The authors — Cinzia Parolini and Núria Mach — survey contributions spanning inflammatory bowel disease, diabetes, kidney disease, skin conditions like psoriasis, and lung inflammation, arguing that the gut microbiome functions as a dynamic immunological and endocrine interface rather than a passive bystander. A central message is that dysbiosis — whether in microbial community composition or metabolic output — can precede disease onset rather than merely reflecting it, suggesting genuine causal potential. The editorial highlights three emergent hypotheses: that immune cell subsets such as CD4⁺ T cells mediate microbial-to-systemic inflammatory signals; that short-chain fatty acids and bile acid derivatives act as hormone-like molecules whose effects depend on host metabolic and hormonal context; and that early dysbiosis signatures may represent preclinical vulnerability windows. Therapeutically, the authors advocate moving beyond conventional probiotics and prebiotics toward synthetic bacterial communities, bacteriophage therapy, targeted metabolite supplementation, and precision dietary strategies. A study within the same Research Topic on acetate supplementation is cited as proof-of-concept for metabolite-based immunomodulation. The overarching call is for multi-omics integration — combining metagenomics, metabolomics, immunophenotyping, and host genetics — to build personalized, rather than universal, microbiota-based interventions.

• The gut microbiota is reframed as a dynamic immunological and endocrine interface influencing metabolism, immune function, and systemic inflammation across multiple organ systems including the kidney, skin, intestine, and lungs.
• Three new hypotheses are proposed: (1) CD4⁺ T cells and tissue-resident lymphocytes act as intermediaries translating microbial signals into systemic inflammation; (2) SCFAs and bile acid derivatives function as endocrine-like molecules shaped by host metabolic and hormonal status; (3) early dysbiosis signatures in IBD and psoriasis may constitute preclinical microbial shifts predisposing to disea
• Acetate supplementation within the associated Research Topic is highlighted as direct evidence that microbial metabolites can be harnessed therapeutically for immunomodulation, illustrating the translational potential of metabolite-based strategies.
• The editorial concludes that inter-individual microbiota variability makes universal therapeutic approaches unlikely to succeed, making personalized, multi-omics-integrated strategies an essential direction for the field.

This is a narrative editorial synthesizing multiple original research articles compiled within a themed Research Topic in Frontiers in Cellular and Infection Microbiology. No primary data, clinical cohort, or experimental intervention was conducted by the authors themselves. The synthesis draws on mechanistic, clinical, and interventional studies submitted to the Research Topic, covering disease areas including IBD, diabetes, psoriasis, kidney disease, and respiratory inflammation. As an editorial, it does not report sample sizes, follow-up durations, or pre-registered methodology.

Because this is an editorial rather than a primary study, it cannot provide mechanistic evidence, effect sizes, or causal inferences of its own — all empirical weight rests on the underlying articles it references, which readers must evaluate independently. The breadth of disease areas covered (IBD, diabetes, skin, kidney, lung) limits depth on any single pathological axis, and the three proposed hypotheses remain speculative frameworks rather than tested claims. Confounding from diet, host genetics, and geography across the cited studies is acknowledged implicitly but not systematically addressed. The next critical experiments would involve longitudinal multi-omics cohort studies in pre-symptomatic individuals to test whether early dysbiosis signatures genuinely precede and predict disease onset in IBD and psoriasis.

This editorial serves as the conceptual anchor for much of the surrounding corpus, providing the overarching immunological and microbiota-disease framework that individual experimental studies extend. Studies such as [§118], examining the anti-colitis effects of a Scilla scilloides mannan via gut microbiota modulation, and [§120], which maps how Eubacterium rectale mitigates IBD through glutamine metabolism and NF-κB signaling, directly instantiate the editorial's argument that specific microbial-metabolite pathways translate dysbiosis into mucosal inflammation. The editorial's hypothesis about preclinical dysbiosis signatures parallels the findings in [§141], where ulcerative colitis-driven gut dysbiosis exacerbates periodontal bone loss through the gut-oral axis, illustrating how microbiota disruption propagates inflammatory consequences beyond the intestine. Its call for multi-omics integration and personalized interventions extends the logic of [§143], which employs multi-omics analysis to characterize how a quadruple probiotic mixture protects against experimental autoimmune hepatitis. Taken together, the editorial contextualizes and gives theoretical coherence to the mechanistic and interventional findings scattered across the corpus.

• Anti-inflammatory and gut microbiota-modulating effects of a novel mannan from Scilla scilloides on DSS-induced colitis in mice
  Tests the editorial's microbiota-modulation-as-therapy hypothesis directly in a DSS-colitis model using a plant-derived mannan, offering experimental grounding for claims about non-probiotic interventions.
• Eubacterium rectale Mitigates Inflammatory Bowel Disease via Modulation of Glutamine Metabolism Through the GLS2 and NF-κB Pathway
  Provides mechanistic depth on a specific strain-level pathway (Eubacterium rectale → glutamine metabolism → NF-κB) that exemplifies the editorial's argument that individual microbial species can drive or resolve mucosal inflammation.
• Ulcerative colitis-driven gut dysbiosis exacerbates periodontal bone loss through the gut-oral axis /Th17/Treg imbalance
  Extends the editorial's preclinical-dysbiosis hypothesis to a gut-oral axis context, showing UC-induced dysbiosis drives distal inflammatory consequences, which challenges intestine-centric framing.
• Multi-omics Analysis Reveals the Protection of a Quadruple Probiotic Mixture in Experimental Autoimmune Hepatitis
  Deploys the multi-omics integration strategy the editorial advocates as a future priority, making it a direct methodological case study for the editorial's translational roadmap.
• The Role of Vitamin D in Inflammatory Bowel Disease: Clinical Relevance and Therapeutic Potential
  Addresses IBD pathophysiology through a complementary immunomodulatory axis (vitamin D) rather than microbiota, enabling readers to compare microbiota-centric versus nutrient-receptor-centric frameworks for the same disease context.